SCHEMBL3158189

SCHEMBL3158189

CC(C)(C)OC(=O)N1CCC(Oc2cc(S(C)(=O)=O)ccc2C(=O)Nc2ccc(Cl)cc2C(=O)Nc2ccc(Cl)cn2)CC1

nearest known ligand 0.51

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
F10 P00742 16/20 0.51
GPR119 Q8TDV5 3/20 0.49
KCNH2 Q12809 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3157349 0.94 GPR119 (0.50) F10GPR119
SCHEMBL3160793 0.94 GPR119 (0.48) F10GPR119
SCHEMBL3160056 0.91 GPR119 (0.48) F10GPR119
SCHEMBL4276095 0.91 GPR119 (0.46) F10GPR119
SCHEMBL4277030 0.91 GPR119 (0.47) F10GPR119
SCHEMBL3160762 0.89 GPR119 (0.45) F10GPR119
SCHEMBL3157662 0.89 F10 (0.50) F10KCNH2
SCHEMBL3160372 0.89 F10 (0.51) F10KCNH2
SCHEMBL3159116 0.88 F10 (0.48) F10KCNH2
Hydrochloric Acid SCHEMBL3156197 0.88 F10 (0.50) F10KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7700628-B2 Aromatic ether derivatives useful as thrombin inhibitors ELI LILLY AND COMPANY (US) 2010-04-20 US disclosed
EP-1817287-B1 AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS LILLY CO ELI (US) 2010-02-10 EP disclosed
US-20090227566-A1 AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS ELI LILLY AND COMPANY 2009-09-10 US disclosed
EP-1817287-A1 AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS Eli Lilly and Company (US) 2007-08-15 EP disclosed
WO-2006057845-A1 AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS ELI LILLY AND COMPANY (US) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227566-A1 AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS TFPI, F2, F11 F10 15/4885GPR119 2215/4885KCNH2 2712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.